Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05698719
Other study ID # FAST STEMI II
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 22, 2022
Est. completion date June 22, 2023

Study information

Verified date January 2023
Source Erasmus Medical Center
Contact Joost Daemen, MD PhD
Phone +31 (0)10 70 388 96
Email j.daemen@erasmusmc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This prospective multicenter observational cohort study is designed to study the diagnostic performance of acute-setting angiography-based FFR (e.g. vFFR) for the physiological assessment of intermediate non-culprit lesions in STEMI patients, with acute-setting FFR and acute-setting NHPR (e.g. RFR) as the reference standards.


Description:

The FAST STEMI II study is an investigator-initiated, multicenter, single-arm, observational cohort study aiming to include 111 patients presenting with ST-elevation myocardial infarction (STEMI). The study is designed to assess the diagnostic performance of acute-setting angiography-based fractional flow reserve (e.g. vessel fractional flow reserve (vFFR)) for the physiological assessment of intermediate non-culprit lesions, with acute-setting fractional flow reserve (FFR) and acute-setting non-hyperemic pressure ratio (NHPR) (e.g. resting full-cycle ratio (RFR)) as the reference standards. Angiography-based FFR has the potential to guide complete revascularization in STEMI patients with multivessel disease, thereby reducing the need for invasive pressure wires and hyperemic agents. However, dedicated data regarding the diagnostic performance of acute-setting angiography-based FFR, with acute-setting FFR and NHPR as the reference standards, is currently lacking for this subset of patients. Of note, FFR slightly underestimates the hemodynamic significance of non-culprit lesions in the acute setting due to microvascular constriction and a blunted hyperemic response, while NHPR slightly overestimates the functional lesion significance. Angiography-based fractional flow reserve is not affected by changes in the microvasculature. Potential discrepancies between acute-setting angiography-based FFR, FFR and NHPR might be explained by the microvascular state, expressed as coronary flow reserve (CFR) and the index of microvascular resistance (IMR). Main objectives: 1. To study the diagnostic performance of acute-setting vFFR for the physiological assessment of intermediate non-culprit lesions in STEMI patients, with acute-setting FFR as the reference standard. 2. To study the diagnostic performance of acute-setting vFFR for the physiological assessment of intermediate non-culprit lesions in STEMI patients, with acute-setting RFR as the reference standards. 3. To study the impact of CFR and IMR on the potential discrepancies between acute-setting vFFR, FFR and RFR.


Recruitment information / eligibility

Status Recruiting
Enrollment 111
Est. completion date June 22, 2023
Est. primary completion date June 22, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older. - At least one intermediate non-culprit lesion (50-90% diameter stenosis by visual estimation or online QCA) in a non-infarct related artery (reference vessel diameter >2.00 mm) for which invasive pressure wire-based physiological assessment is deemed feasible and indicated. Exclusion Criteria: - Presentation with cardiac arrest or cardiogenic shock. - Previous coronary artery bypass graft surgery or percutaneous coronary intervention involving the non-culprit vessel. - Ostial left main or ostial right coronary artery lesion. - Excessive overlap, foreshortening or tortuosity precluding vFFR computation.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands Erasmus University Medical Center Rotterdam
Poland Medical University of Warsaw Warsaw

Sponsors (1)

Lead Sponsor Collaborator
Erasmus Medical Center

Countries where clinical trial is conducted

Netherlands,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary The diagnostic performance of acute-setting vFFR for the physiological assessment of intermediate non-culprit lesions, with acute-setting FFR as the reference standard. Diagnostic performance: sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive value (ischemic cutoff value acute-setting vFFR and acute-setting FFR: =0.80). Intraprocedural (0 days)
Secondary The diagnostic performance of acute-setting vFFR for the physiological assessment of intermediate non-culprit lesions, with acute-setting RFR as the reference standard. Diagnostic performance: sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive value (ischemic cutoff value acute-setting vFFR: =0.80; acute-setting RFR: =0.89). Intraprocedural (0 days)
Secondary The diagnostic performance of acute-setting RFR for the physiological assessment of intermediate non-culprit lesions, with acute-setting FFR as the reference standard. Diagnostic performance: sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive value (ischemic cutoff value acute-setting RFR: =0.89; acute-setting FFR: =0.80). Intraprocedural (0 days)
Secondary The diagnostic performance of acute-setting vFFR for the physiological assessment of intermediate non-culprit lesions, with offline dPR as the reference standard. Diagnostic performance: sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive value (ischemic cutoff value acute-setting vFFR: =0.80; offline dPR: =0.89). Postprocedural (max. 7 days)
Secondary The diagnostic performance of offline vFFR for the physiological assessment of intermediate non-culprit lesions, with acute-setting FFR and RFR as the reference standards. Diagnostic performance: sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive value (ischemic cutoff value offline vFFR: =0.80; acute-setting FFR: =0.80; acute-setting RFR: =0.89). Postprocedural (max. 7 days)
Secondary The diagnostic performance of offline vFFR for the physiological assessment of intermediate non-culprit lesions, with offline dPR as the reference standard. Diagnostic performance: sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive value (ischemic cutoff value offline vFFR: =0.80; offline dPR: =0.89). Postprocedural (max. 7 days)
Secondary The correlation between CFR and the potential discrepancies between acute-setting vFFR, FFR and RFR. The microvascular state is expressed as coronary flow reserve (CFR). Intraprocedural (0 days)
Secondary The correlation between IMR and the potential discrepancies between acute-setting vFFR, FFR and RFR. The microvascular state is expressed as the index of microvascular resistance (IMR). Intraprocedural (0 days)
See also
  Status Clinical Trial Phase
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Not yet recruiting NCT05669222 - The FAVOR V AMI Trial N/A
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05240781 - Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk N/A
Recruiting NCT03378934 - Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention Phase 4
Not yet recruiting NCT06025071 - Residual Inflammatory Risk-Guided colcHicine in Elderly Trial Phase 4
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Completed NCT02837744 - Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
Completed NCT03085823 - The All-comers Sirolimus-coated Balloon European Registry
Completed NCT02044146 - A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk Phase 2/Phase 3
Completed NCT03131271 - Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention N/A
Completed NCT01135667 - Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI Phase 4
Completed NCT01156571 - A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) Phase 3
Unknown status NCT00751491 - Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT00725868 - Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention N/A
Completed NCT03708588 - Chewed Versus Integral Pill of Ticagrelor Phase 4
Completed NCT04163393 - R-One Efficiency For PCI Evolution With Robotic Assistance N/A
Recruiting NCT05554588 - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI N/A
Recruiting NCT06080919 - Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI). N/A
Recruiting NCT05353140 - LAAO Versus NOAC in Patients With AF and PCI N/A